Dual checkpoint inhibitor-associated eosinophilic enteritis

Yang, J.; Lagana, S. M.; Saenger, Y. M.; Carvajal, R. D.

Eosinophilia has been reported as a rare, new biological effect of immune checkpoint inhibition that may be associated with improved treatment response and the development of immune-related adverse events.

Case presentation
We report a case of dual checkpoint inhibitor-associated hypereosinophilia and eosinophilic enteritis in a patient with advanced cutaneous melanoma. Rapid resolution of peripheral eosinophilia and associated symptoms was achieved with steroids alone.

Immune checkpoint inhibition can trigger inflammation in virtually any organ in the body, leading to diverse clinical manifestations. To our knowledge, this is the first case report of eosinophilic enteritis due to ipilimumab plus nivolumab.


  • thumnail for 40425_2019_Article_743.pdf 40425_2019_Article_743.pdf application/pdf 427 KB Download File

Also Published In

Journal for ImmunoTherapy of Cancer

More About This Work

Published Here
September 22, 2023


Melanoma, Checkpoint inhibition, Eosinophilia, Eosinophilic enteritis